Quantum-Si incorporated (QSI)
Nasdaq · Healthcare · Medical Devices
$1.28−17.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $280M
- 52-week range
- $0.69 – $3.10
- 52-week change
- −12.43%
- EPS (trailing)
- −$0.45
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $2.4M (−20.34%)
- Net income
- −$101M
- Operating margin
- −4766.0%
- Diluted EPS
- −$0.51
- Free cash flow
- −$97.2M
From the company’s annual report on SEC EDGAR.
About Quantum-Si incorporated
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Headquarters: Branford, United States · 145 employees · quantum-si.com